Arora, Ashish and Gambardella, Alfonso and Magazzini, Laura and Pammolli, Fabio (2007): A Breath of Fresh Air? Firm types, scale, scope and selection effects in drug development.
Download (221kB) | Preview
This paper measures differences in the innovation performance of different types of firms in the pharmaceutical industry. We compare the innovation performance of incumbent firms with entrants, controlling for differences in the scale and scope of research, both at the firm level and at the project level. To do so, we develop a simple analytical framework of drug development, which we use to estimate a structural model, using data on 3,000 drug R&D projects in preclinical and clinical trials in the US during the 1980s-early 1990s. Key to our approach is a careful attention to the issue of selection – firms choose which compounds to advance into clinical trials. This choice depends upon the likelihood of success, but also upon economies of scale and scope, and strategic considerations about product cannibalization. It also depends upon how the costs of development and the rewards of success are shared within organizations and between alliance partners. After controlling for selection, we find that: a) incumbent pharmaceutical firms draw their compounds from better statistical distributions; b) over time, learning or environmental selection make entrants firms more similar to the established firms both in terms of selection behavior and research productivity; c) compounds licensed by pharmaceutical firms are at least as likely to succeed as internal developed projects, inconsistent with the “lemons” hypothesis; d) firm scale improves innovation performance but not scale at the project level.
|Item Type:||MPRA Paper|
|Original Title:||A Breath of Fresh Air? Firm types, scale, scope and selection effects in drug development|
|Keywords:||firm capabilities; drug development process; market for technology|
|Subjects:||L - Industrial Organization > L2 - Firm Objectives, Organization, and Behavior > L25 - Firm Performance: Size, Diversification, and Scope|
|Date Deposited:||23. Jul 2009 06:02|
|Last Modified:||07. Jan 2014 21:30|
Abrantes-Metz, R., Adams C., Metz A., 2006: “Pharma Development Phases: A Duration Analysis”. Journal of Pharma Finance, Economics and Policy 14(4) 19-41.
Acs, Z., Audtretsch D., 1990: Innovation and Small Firms. Cambridge MA. MIT Press.
Adams, C., Brantner V., 2003: “New Drug Development: Estimating Entry from Human Clinical Trails”. FTC Working Paper #262.
Akerlof, G.A. 1970: “The Market for ‘Lemons’: Quality Uncertainty and the Market Mechanism”. Quarterly Journal of Economics 84 488-500.
Arora, A., Fosfuri A., Gambardella A., 2001: Markets for Technology: The Economics of Innovation and Corporate Strategy. Cambridge MA. MIT Press.
Arora, A., Gambardella A., 1994: “Evaluating Technological Information and Utilizing it”. Journal of Economic Behavior and Organization 24 91-114.
Arrow, K.J. 1962: Economic welfare and the allocation of resources for invention, in: R.R.Nelson (ed.), The rate and direction of inventive activity, Princeton University Press: Princeton, 609-624.
Arrow, K.J. 1983: Innovation in Large and Small Firms. In Ronen J. (ed.) Entrepreneurship. Lexington MA. Lexington Books.
Braunwald, E., Fauci A.S., Casper D.L., Hauser S.L., Longo D.L., Jameson J.L., 2001: Harrison’s Principle of Internal Medicine. 15th edition. Mc Graw-Hill.
Chesbrough, H., Teece D.J., 1996: “When is Virtual Virtuous? Organizing for Innovation”. Harvard Business Review 74(1) 65-72.
Christensen, C. 1997: The Innovator's Dilemma. Boston: Harvard Business School Press.
Cohen, W.M., Levinthal D., 1989: “Innovation and Learning: the Two Faces of R&D”. Economic Journal 99(397) 569-596.
Cohen, W., Levinthal D. 1990: “Absorptive Capacity: A New Perspective on Learning and Innovation”. Administrative Science Quarterly 35 128-152.
Danzon, P.M., Nicholson S., Pereira N.S., 2005: “Productivity in Pharma-Biotechnology R&D: the Role of Experience and Alliances”. Journal of Health Economics 24 317-339.
Dasgupta, P., David P.A., 1994: “Toward a new economics of science”. Research Policy, 23(5) 487-521.
DiMasi, J.A., Hansen R.W., Grabowski H.G., 2003: “The Price of Innovation: New Estimates of Drug Development Costs”. Journal of Health Economics 22(2) 151-186.
Gambardella, A. 1995: Science and Innovation in the US Pharma Industry. Cambridge UK: Cambridge University Press.
Giarratana, M.S. 2004: “The Birth of a New Industry: Entry by Start-Up and the Drivers of Firm Growth. The Case of Encryption Software”. Research Policy 33 787-806.
Grabowski, H.G., Vernon J., DiMasi J.A., 2002: Returns on R&D for 1990s New Drug Introductions. www.dklevine.com/archive/grabow-randd_returns.pdf.
Guedj, I., Scharfstein D., 2005: Organizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms. NBER Working Paper 10933. Cambridge MA.
Heckman, J.J. 1979: “Sample Selection Bias as a Specification Error”. Econometrica 47(1) 153-161.
Henderson, R., Clark K., 1990: “Architectural Innovation: The Reconfiguration of Existing Product Technologies and the Failure of Established Firms”. Administrative Science Quarterly 35(1) 9-30.
Henderson, R., Cockburn I., 1996: “Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery”. RAND Journal of Economics 27(1) 32-59.
Higgins, M.J., Rodriguez D., 2006: “The outsourcing of R&D through acquisition in the pharmaceutical industry”. Journal of Financial Economics 80 351-383.
Holmstrom, B. 1989: “Agency Costs and Innovation”. Journal of Economic Behavior and Organization 12(3) 305-327.
Levinthal, D., March J., 1993: “The Myopia of Learning”. Strategic Management Journal 14 95-112.
Macher, J.T., Boerner C.S., 2006: “Experience and Scale and Scope Economies: Trade-Offs and Performance in Development”. Strategic Management Journal 27 845-865.
Nerkar, A. 2003: The Folly of Rewarding Patents and Expecting FDA Approved Drugs. Working paper.. http://bschool.washington.edu/departments/mo/PDF/Nerkar_UW.pdf., Retrieved 27 Feb, 2007.
Nerkar, A., Roberts P., 2004: “Technological and Product-Market Experience and the Success of New Product Introductions in the Pharma Industry”. Strategic Management Journal 25 779-799.
Pammolli, F., Riccaboni M., 2004: Technological Competencies in Networks of Innovators. In Cantwell, J., A. Gambardella, O. Granstrand (eds.). The Economics and Management of Technological Diversification. London and New York: Routledge.
Pisano, G. 1997: R&D Performance, Collaborative Arrangements, and the Market for Know-How: A Test of the “Lemons” Hypothesis in Biotechnology”. Mimeo. Harvard Business School, Cambridge MA.
Pisano, G. 2006: “Can Science Be a Business? Lessons from Biotech”. Harvard Business Review 84(10) 114-124.
Powell, W., Koput K., Smith-Doerr L., 1996: “Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology”. Administrative Science Quarterly 41 116-145.
Reddy, K.A. 2003: “The agony and ecstasy of Drug Discovery”. CRIPS 4(1) 10-12.
Rosenberg, N. 1990: “Why Do Firms Do Basic Research (With Their Own Money)?”. Research Policy 19 165-174.
Shaver, J.M. 1998: “Accounting for Endogeneity When Assessing Strategy Performance: Does Entry Mode Choice Affect FDI Survival?”. Management Science 44(4) 571-585.
Stiglitz, J. E., Weiss A., 1981: “Credit Rationing in Markets with Imperfect Information”. The American Economic Review 71(3) 393-410.
Thompke, S., Kuemmerle W., 2002: “Asset Accumulation, Interdependence And Technological Change: Evidence From Pharmaceutical Drug Discovery”. Strategic Management Journal 23(7) 619-635.
U.S. Congress, Office of Technology Assessment (OTA). 1993: Pharmaceutical R&D: Costs, Risks and Rewards. U.S. Government Printing Office, Washington, DC.
U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research. 1999: From Test Tube to Patient: Improving Health Through Human Drugs (special report). U.S. Government Printing Office, Washington, DC.